Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of a domestic 9-valent HPV vaccine vs Gardasil 9 in Chinese women 16–26 years
CTR20201389Phase 3Completed
- Sponsor
- Shanghai Bowei Biopharmaceutical
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus 9-valent vaccine, recombinant in human papillomavirus infection, Cervical Cancer (CC), vaginal cancer, Vulval carcinoma, anogenital intraepithelial neoplasia (AIN), sponsored by Shanghai Bowei Biopharmaceutical. Started Jul 2020; status: completed.
02
Drugs
human papillomavirus 9-valent vaccine, recombinant
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vaginal cancerVulval carcinomaanogenital intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on CTR20201389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201389.